{"entity":{"id":"rachel-rau","kind":"person","name":"Rachel E. Rau","aka":[],"tldr":"Paediatric oncologist who led the COG trial showing blinatumomab helps children with standard-risk leukaemia.","summary":"Rachel Rau is Associate Professor of Pediatrics at Seattle Children's and the University of Washington and Study Chair of COG AALL1731 within the Children's Oncology Group (COG). A paediatric haematologist-oncologist specialising in paediatric acute lymphoblastic leukaemia, immunotherapy and leukaemia genomics, she led the COG trial that found adding blinatumomab to chemotherapy helps children with newly diagnosed standard-risk B-ALL. Her papers report blinatumomab in standard-risk B-cell acute lymphoblastic leukaemia in children in the New England Journal of Medicine and a Blood study of DOT1L as a therapeutic target in DNMT3A-mutant acute myeloid leukaemia. Her work centres on CD19-directed immunotherapy in childhood leukaemia.","asOf":"2026-09-08","links":[{"label":"Children's Oncology Group","url":"https://childrensoncologygroup.org"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rau%20RE%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Rachel%20E.%20Rau"}],"tags":[],"related":[],"cancers":["all-leukemia"],"sections":[],"technologies":[],"targets":["cd19"],"drugs":["blinatumomab"],"companies":["childrens-oncology-group"],"institutions":[],"pathways":[],"terms":[],"trials":["aall1731"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Associate Professor of Pediatrics, Seattle Children's and University of Washington; Study Chair, COG AALL1731","institutionId":"childrens-oncology-group","specialisms":["Paediatric ALL","Immunotherapy","Leukaemia genomics"],"profiles":[{"label":"Children's Oncology Group","url":"https://childrensoncologygroup.org"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rau%20RE%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Rachel%20E.%20Rau"}],"papers":[{"title":"Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children","journal":"New England Journal of Medicine","year":2025,"url":"https://doi.org/10.1056/NEJMoa2411680","doi":"10.1056/NEJMoa2411680"},{"title":"DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia","journal":"Blood","year":2016,"url":"https://doi.org/10.1182/blood-2015-11-684225","doi":"10.1182/blood-2015-11-684225"},{"title":"Children's Oncology Group AALL1731: blinatumomab added to chemotherapy for children with standard-risk B-cell ALL","journal":"New England Journal of Medicine","year":2025,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AALL1731%20blinatumomab%20standard-risk%20B-ALL%20children%20Gupta%20NEJM%202025"}],"orcid":"0000-0003-4096-6603"},"route":"/people/rachel-rau/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"}],"drug":[{"id":"blinatumomab","kind":"drug","name":"Blinatumomab","route":"/drugs/blinatumomab/"}],"company":[{"id":"childrens-oncology-group","kind":"company","name":"Children's Oncology Group (COG)","route":"/companies/childrens-oncology-group/"}],"trial":[{"id":"aall1731","kind":"trial","name":"COG AALL1731","route":"/trials/aall1731/"}],"paper":[{"id":"paper-aall1731-blinatumomab-children-nejm-2025","kind":"paper","name":"Children's Oncology Group AALL1731: blinatumomab added to chemotherapy for children with standard-risk B-cell ALL","route":"/key-papers/paper-aall1731-blinatumomab-children-nejm-2025/"}]}}